Follow us on Twitter
twitter icon@FreshPatents

Receptor patents

Bulk PDF Downloads
      

This page is updated frequently with new Receptor-related patent applications.




 Semiconductive roller patent thumbnailnew patent Semiconductive roller
A semiconductive roller is provided, which is capable of uniformly electrically charging a surface of a photoreceptor body particularly when being used as a charging roller, substantially free from defective image formation due to adhesion and accumulation of external additives even if repeatedly performing a charging operation, and less liable to contaminate the photoreceptor body, and has a lower roller resistance to make it possible to form higher-definition images at a higher process speed. The semiconductive roller (1) is formed from a semiconductive rubber composition which contains a rubber component including 15 to 80 mass % of an epichlorohydrin rubber, 5 to 50 parts by mass of titanium oxide based on 100 parts by mass of the rubber component, and a potassium salt as an electrically conductive agent.
Sumitomo Rubber Industries, Ltd.


 Marker of cell death patent thumbnailnew patent Marker of cell death
The present invention relates to methods for detecting cell death in a cell or a sample comprising cells, or in cultured cells in vitro by detecting the level of calcitonin receptor. The present invention also relates to methods of imaging cell death in a subject, compositions useful for detecting cell death in a cell or in a subject, methods of screening for modulators of cell death, and methods of staging and monitoring the progress of disease by detecting cell death..
Welcome Receptor Antibodies Pty Ltd


 Multiplex mrm assay for evaluation of cancer patent thumbnailnew patent Multiplex mrm assay for evaluation of cancer
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (er), progesterone receptor (pr), and/or antigen ki67 (ki67) proteins that are particularly advantageous for quantifying the er, pr, and/or ki67 proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Expression Pathology, Inc.


 Organic compounds patent thumbnailnew patent Organic compounds
The present invention relates to modulators of the interaction between g-protein coupled receptor 15(gpr15) and c10orf99. The modulator maybe a small chemical molecule, antibody or other therapeutic protein.
Euroscreen S.a.


 Screening assay for agents that influence beta cell number and/or phenotype patent thumbnailnew patent Screening assay for agents that influence beta cell number and/or phenotype
The present invention in general relates to a method for identifying compounds that influence beta cell number and/or phenotype, more in particular beta cell differentiation, proliferation and/or expansion. Said method comprising culturing beta cells or precursors thereof in 5 medium comprising glucose, and determining the ability of said compound to induce the glucocorticoid receptor dependent-transactivation pathway in said beta cells.
Opus Nv


 Methods and materials for producing transgenic artiodactyls patent thumbnailnew patent Methods and materials for producing transgenic artiodactyls
Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a low-density lipoprotein receptor gene ldlr, duchene's muscular dystrophy (dmd) gene, and hairless gene (hr). Methods of preparing transfected cells useful for making a transgenic animal comprising exposing a first group of cells to a transfection agent and reseeding the group with additional cells that have not been exposed to the agent.
Recombinetics, Inc.


 Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system patent thumbnailnew patent Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive t-cells for immunotherapy. This method involves the use of rna-guided endonucleases, in particular cas9/crispr system, to specifically target a selection of key genes in t-cells.
Cellectis


 Ntrk2 fusions patent thumbnailnew patent Ntrk2 fusions
The invention provides to ntrk (“neurotrophic tyrosine receptor kinase) gene fusions, ntrk. Fusion proteins, and fragments of those genes and polypeptides.
Blueprint Medicines Corporation


 Smart car devices, de car polypeptides, side cars and uses thereof patent thumbnailnew patent Smart car devices, de car polypeptides, side cars and uses thereof
The present invention relates generally to the field of rna control devices and/or destabilizing elements (de) combined with chimeric antigen receptors (cars) in eukaryotic cells. The present invention also relates to split cars (side-cars) in eukaryotic cells.
Chimera Bioengineering, Inc.


 Treatment of c1013g/cxcr4-associated waldenstrÖm's macroglobulinemia with an anti-cxcr4 antibody patent thumbnailnew patent Treatment of c1013g/cxcr4-associated waldenstrÖm's macroglobulinemia with an anti-cxcr4 antibody
The present disclosure provides a method for treating a subject afflicted with waldenstrm's macroglobulinemia (wm) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a cxcr4 receptor expressed on the surface of a wm cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with c1013g/cxcr4-associated wm..
Dana-farber Cancer Institute, Inc.


new patent

Chemokine receptor binding polypeptides


The present invention relates to polypeptides directed against or specifically binding to chemokine receptor cxcr2 and in particular to polypeptides capable of modulating signal transduction from cxcr2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of cxcr2..
Novartis Ag


new patent

Anti-kir antibodies


Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (kir)-targeting agents) that target a subset of t lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-kir antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.)..
The Regents Of The University Of Michigan


new patent

Anti-nerve growth factor antibodies and methods of preparing and using the same


A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to feline neuronal growth factor (ngf) and neutralise the ability of feline ngf to bind to the p75 or trka feline ngf receptor.
Nvip Pty Ltd


new patent

Protamine in treatment of neuronal injuries


The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite out growth and/or neural regeneration in cns injuries.
University Of Helsinki


new patent

Novel amylin and calcitonin receptor agonist


The present invention relates to peptides comprising an amino acid sequence seq id no: 1 (easelstaalgrlsaelhelatlprtetgpesp), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to seq id no: 1, analogues and derivatives thereof as medicaments..
Novo Nordisk A/s


new patent

3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof


Disclosed are a 3-furyl-2-cyano-2-acrylamide derivative with epidermal growth factor receptor (egfr) inhibitory activity and pharmaceutical acceptable salt thereof, together with preparation method thereof, pharmaceutical composition comprising the compound, and application of the compound in treating senile dementia (ad). The new compound is shown as formula i, wherein r1 is selected from the group consisting of h, c1-c6 alkyl, c2-c6 alkenyl, c2-c6 alkynyl and c3-c6 cycloalkyl; r2 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl and heteroaralkyl; x is selected from the group consisting of ch2, nh, o and s; m and n are all integers greater than or equal to zero..
Jenkem Technology Co., Ltd. (beijing)


new patent

Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor


The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-ht2a serotonin receptor modulators, compositions thereof and methods of using the same..

new patent

Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators


The present invention provides a compound of the formula (i): wherein x, r, r1, r2, r3, r4, r5, r6, r7, r8, and r9 are as defined herein, or a pharmaceutically acceptable salt thereof.. .
Eli Lilly And Company


new patent

Phenylcarbamate derivatives as formyl peptide receptor modulators


The present invention relates to n-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide 2 receptor.. .
Allergan, Inc.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.
new patent

Novel ceramide derivatives having agonistic effects on epidermal cannabinoid receptors, and pharmaceutical or cosmetic composition containing same


The present invention relates to a novel pseudoceramide derivative, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical or cosmetic composition containing the same as an active ingredient. The novel pseudoceramide derivative of the present invention is expected to be very useful for treating or preventing skin diseases by activating cannabinoid receptors.
Neopharm Co., Ltd.


new patent

Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals


Wherein a, y, z, r3 to r6, r20 to r22 and r50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (edg-2, edg2), which is activated by lysophosphatidic acid (lpa) and is also termed as lpa1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example.

new patent

Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels


Nanostructure conjugates, methods for their preparation, and methods for their use are described. The nanostructure conjugates are useful in inhibiting, activating, and modulating extrasynaptic receptors and ion channels, and in treating various medical conditions among other attractive uses..

new patent

Peptidic nanodelivery composition targeting two receptors


A polypeptide conjugate for use in a method for binding and/or internalization of the polypeptide conjugate to a mammalian cell having a transferrin receptor (tfrc) and/or receptor for advanced glycation end products (rage). The polypeptide conjugate may be used in a method for targeting of a drug delivery system or diagnostic delivery system..

new patent

Dual peptide-mediated targeted delivery system


This invention is generally related to a dual-peptide delivery system, where one peptide exhibits a receptor-targeting moiety and the other peptide exhibits an endosome-disruptive bioactivity.. .
Clemson University


new patent

Low molecular weight immune-modulators as adjuvants for specific immunotherapy


The invention relates to a pharmaceutical composition for local modulation of t cell and b cell responses at the site of allergen or antigen presentation, made of one or more preparations comprising one or more antigens or allergens, and a therapeutically effective dose of two or more low molecular weight immune modulators selected from four groups of tolerance-inducing therapeutics comprising inhibitors of complement-mediated functions, inhibitors of tumor necrosis factor receptor 1 (tnfr1)-mediated functions, inhibitors of interleukin 4- and interleukin 13-mediated functions, and therapeutic agents suitable for vitamin d3 supplementation wherein preferably two or more low molecular weight immune modulators and one or more antigens or allergens are coated or adsorbed on or embedded in a matrix, wherein the matrix is selected as to enable sustained release of one or more antigens or allergens and two or more immune modulators for the treatment of t cell-mediated diseases.. .
Helmholtz Zentrum MÜnchen Forschungszentrum FÜr Gesundheit Und Umwelt Gmbh


new patent

Recombinant t-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction


Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (mhc) molecule including covalently linked first, second, and third domains; wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain; or wherein the first domain is an mhc class i α1 domain and the second domain is an mhc class i α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system..
The United States Government As Represented By The Department Of Veterans Affairs


new patent

Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies


The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.. .
University Of Florida Research Foundation, Inc.


new patent

Methods of treating heart failure with agonists of hypocretin receptor 2


Methods of treating individuals for heart failure are disclosed. In particular, the invention relates to methods of treating individuals for heart failure with agonists of hypocretin receptor 2.
The Board Of Trustees Of The Leland Stanford Junior University


new patent

Reelin rescues cognitive function


Disclosed are methods of influencing, and enhancing, cognitive function by increasing, and/or preventing interference with, reelin levels as well as reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of reelin, a reelin-specific modulator or an agonist of a lipoprotein receptor to the subject.
Vanderbilt University


new patent

Modulators of syndecan-2 and uses thereof


Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a th17 mediated disease such as an autoimmune disease, fibrosis or cancer.. .
Orbsen Therapeutics Limited


new patent

Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps


Disclosed herein is a therapeutic intervention to prevent, reduce, or treat hemodialysis-associated skeletal muscle cramps by administering all receptor agonists or other pharmacologic agents that augment homeostatic responses to hemodialysis while preventing derecruitment of skeletal muscle capillaries.. .
Atkinson, Arthur J.


new patent

Method for treating haemorrhage, shock and brain injury


The invention relates to a composition and method for increasing blood pressure, including a low pain or analgesic state or hypotensive anaesthesia in a subject that has suffered a life threatening hypotension or shock or reducing hypofusion in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; and (ii) an antiarrhythmic agent or a local anaesthetic..
Hibernation Therapeutics, A Kf, Llc


new patent

Anti-cancer compounds and methods for treating cancer


The present invention is directed to novel anti-cancer compounds and methods of treating and/or inhibiting cancer in patients, including metastatic cancer, recurrent cancer and drug resistant cancers, including multiple drug resistant cancers. Compounds according to the present invention provide anti-cancer activity, at least in part, by virtue of their nucleotide intercalating activity through the use of analogs of (−)lomaiviticin a, a potent anticancer agent which exhibits cytotoxicity through its principal mechanism of cleavage and to a lesser extent, its intercalation of cellular polynucleotides, especially dna.
Yale University


new patent

Estrogen receptor modulators for reducing body weight


The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (erm), optionally, in combination with an anti-obesity or weight loss agent.. .
Rosscreening, Inc.


new patent

Fused benzazepines for treatment of stuttering


The present invention encompasses methods of treating a subject who stutters. The methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a d1/d5 receptor antagonist, a d1/d5 receptor partial agonist, or a mixture thereof.
Psyadon Pharmaceuticals ,inc.


new patent

Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases


Wherein d, x, y, r1, r2, r3, r4, r5, r6, r7 and r8 are as defined herein.. .

new patent

Cannabinoid receptor modulators


Provided are certain methods useful in the treatment of pain comprising administering a compound of formula ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor;. .
Arena Pharmaceuticals, Inc.


Arrangement of coil wires in a rotor of an electric motor


An armature may include a rotor with a plurality of teeth, at least one insulator covering at least a part the teeth, a plurality of coils wound on the teeth, and a plurality of cavities. Each one of the cavities may be arranged between two of the teeth and may be formed on the at least one insulator.
Nidec Motors & Actuators (germany) Gmbh


Analysis, secure access to, and transmission of array images


Systems and methods are provided the autocentering, autofocusing, acquiring, decoding, aligning, analyzing and exchanging among various parties, images, where the images are of arrays of signals associated with ligand-receptor interactions, and more particularly, ligand-receptor interactions where a multitude of receptors are associated with microparticles or microbeads. The beads are encoded to indicate the identity of the receptor attached, and therefore, an assay image and decoding image are aligned to effect the decoding.
Bioarray Solutions, Ltd.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Compositions and methods for diagnosing and/or treating influenza infections


The present invention provides ha polypeptides (e.g., h1 ha polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to ha polypeptides (e.g., h1 ha polypeptides), and reagents and methods relating thereto.
Massachusetts Institute Of Technology


Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use


The present invention describes generation and the use of adenovirus variants (ad) possessing modified capsid penton base protein where mutations in the penton based rgd loop are made to avoid ad binding to cellular β3-integrins. Specifically, the ablation of ad penton base interaction with cellular β3-integrins results in reduced activation of inflammation after intravenous ad administration.

Anti-erbb3 antibodies


Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member erbb3/her3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of erbb3/her3..
Aveo Pharmaceuticals, Inc.


Antibodies reactive with b7-h3 and uses thereof


The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers..
Macrogenics, Inc.


Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target


The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


Binding-triggered transcriptional switches and methods of use thereof


The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids.
The Regents Of The University Of California


Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides


The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (rbd) of the spike (s) glycoprotein of the middle east respiratory syndrome coronavirus (mers-cov). The polypeptides and fusion proteins can be used to treat and prevent mers-cov infection in mammals..
The University Of Hong Kong


Variant activin receptor


The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
Amgen Inc.


Method for improving the specific effector functions of single-chain-antigen-recognizing genetic constructs (scarc) through murinization thereof


The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scarc), comprising a genetic construct of the human scarc to be expressed, comprising the domains huv1/2-li-huv2/1-c4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain c3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains c4/3 and c3/4, wherein co-expression of the genetic constructs of the scarc-fragments occurs through the cell. Preferably, the scarcs are single chain-tcrs (sctcrs) or antibody-scfv-fragments, which further preferably recognize tumor associated peptide antigens (taa).
Johannes Gutenberg-universität Mainz


Glycoprotein hormone long-acting superagonists


This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity..
Trophogen Inc.


Advantageous mu-opiate receptor peptide compounds


The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity..
Cytogel Pharma, Llc


Therapeutic compounds and methods


Regulator of g protein signaling (rgs) proteins modulate the complex signaling pathways elicited by g protein coupled receptor activation. Recent studies have implicated rgs proteins in the development and progression of multiple cancers.
University Of Iowa Research Foundation


Substituted benzamides


Compounds of formula i have a good affinity to the trace amine associated receptors (taars), especially for taar1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (adhd), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as parkinson's disease, neurodegenerative disorders such as alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders..

Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors


The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.. .
Dr. Reddy's Laboratories Ltd.


Itraconazole analogs and use thereof


Provided herein are itraconazole analogs. Also provided herein are methods of inhibition of hedgehog pathway, vascular endothelial growth factor receptor 2 (vegfr2) glycosylation, angiogenesis and treatment of disease with itraconazole analogs..
The Johns Hopkins University


Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4-4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof


The present invention relates to compounds having at least one (substituted phenyl)-propenal moiety. The compounds are useful in treating a subject suffering from an androgen receptor-associated medical condition, e.g., inflammation, acne, alopecia, hirsutism, wound, spinal and bulbar muscular atrophy (sbma, kennedy's disease), unwanted immune response, immune disorder, or cancer..
Allianz Pharmascience Ltd.


Positron emitting radionuclide labeled peptides for human upar pet imaging


There is provided a positron-emitting radionuclide labelled peptide for non-invasive pet imaging of the urokinase-type plasminogen activator receptor (upar) in humans. More specifically the invention relates to human upar pet imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence..
Curasight Aps


Folate receptor binding conjugates of antifolates


Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations.
Endocyte, Inc.


Formulations useful in the treatment of proliferative diseases affecting the respiratory tract


The present application provides a pharmaceutical formulation comprising a folate receptor (fr)-targeting antineoplastic substance or composition, wherein the pharmaceutical formulation is configured for administration by inhalation, wherein the fr-targeting antineoplastic substance or composition is comprised in a nanoparticle and wherein the nanoparticles are comprised in microparticles, and its use in the treatment of a proliferative disease affecting at least part of the respiratory tract. The present application further provides a pharmaceutical formulation comprising an antineoplastic agent and a fr-targeting excipient, for use in the treatment of a proliferative disease affecting at least part of the respiratory tract..
Universite Libre De Bruxelles


Hpyy(1-36) having a beta-homoarginine substitution at position 35


The invention relates to pyy compounds having the amino acid in the position corresponding to position 35 of hpyy(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hpyy(1-36). The compounds of the invention are selective y2 receptor agonists.
Novon Nordisk A/s


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Pif-transfected cells and methods of use


Cells transfected with dna sequences encoding for a preimplantation factor (pif) or a pif and one or more fusion tag(s) are disclosed. Also disclosed are dna sequences encoding for synthetic pifs, a pif fusion peptide made of a pif and one or more fusion tags, methods of treatment using the transfected cells that express a pif, an r-i-k-p peptide, compositions containing the r-i-k-p peptide, and methods of identifying a compound that binds to an active site of an wx1wx2x3x4rewfx5x6x7w receptor, wherein each x can be any amino acid..
Bioincept, Llc


Modified binding proteins inhibiting the vegf-a receptor interaction


The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
Molecular Partners Ag


Methods of controlling vascularity using raver2 as a mediator for expression of vegf receptor sfit1


Methods of treating a condition in a subject resulting from abnormally high vegf signaling through membrane-bound receptors. Such a method can include increasing expression of raver2 in affected cells of the subject to increase production of soluble vegf receptors.
University Of Utah Research Foundation


Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof


A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject.
Rappaport Family Institute For Research In The Medical Sciences


T cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof


The technology relates in part to compositions and methods for inducing an immune response against the preferentially expressed antigen of melanoma (prame). Provided are methods for treating hyperproliferative diseases by inducing an immune response against prame antigen; the immune response may be induced by specifically targeting prame-expressing cells using t cell receptors directed against prame..
Leiden University Medical Center


Use of a3 adenosine receptor agonist in osteoarthritis treatment


Provided is an a3 adenosine receptor agonist (a3ar agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (oa), as well as to a method for the treatment of oa in a mammal subject, the method includes administering to said subject in need of said treatment an amount of a3ar agonist, the amount being effective to treat or prevent the development of oa. Preferred but not exclusive a3ar agonists in accordance with the present subject matter are ib-meca and cl-ib-meca.
Can-fite Biopharma Ltd.


Organ arrest, protection and preservation


The present invention further provides a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.. .

Multidrug infusion for pain control


The present invention relates to a formulation comprising an opioid, a na channel blocker, an alpha2-receptor agonist, an opioid mu or delta receptor competitive antagonist and an intravenous anesthetic and/or a neurologic acting agent for use in pain control and/or cognitive function improvement.. .

S1p modulating agents


Compounds of formula (i) or (ii) can modulate the activity of s1p receptors.. .

Dosage regimen for a s1p receptor agonist


S1p receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.. .
Novartis Ag


Controlled release dosage form


The present invention provides a simple and improved dose form that is capable of providing a controlled release of gabab receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to gabab receptor agonist..
Osmotica Kereskedelmi Es Szolgaltato Kft


Articles to manipulate the temperature of body extremities


Temperature of the extremities is a significant factor in temperature control of the body due to the presence of thermal receptors in the extremities. The brain uses signals from these thermal receptors as an indication of environmental conditions, and responds accordingly.
Geelux Holdings, Ltd.


Automated control of image exposure parameters in an intra-oral x-ray system


Methods and systems for operating x-ray system. One system includes an x-ray source having a plurality of exposure parameters and a controller for the x-ray source.
Dental Imaging Technologies Corporation


Ophthalmic apparatus and control the same


Provided is an ophthalmic apparatus, including: an acquisition unit configured to acquire a confocal image and a nonconfocal image of an eye to be inspected (e); a first detection unit configured to detect a photoreceptor cell of the eye to be inspected (e) from the confocal image; a second detection unit configured to detect a photoreceptor cell of the eye to be inspected (e) from the nonconfocal image; and a display unit configured to compare the photoreceptor cell detected by the first detection unit and the photoreceptor cell detected by the second detection unit with each other to display a result of the comparison on a screen.. .
Canon Kabushiki Kaisha


Bioactive peptides having insecticide activity


Disclosed are novel bioactive peptides derived as antagonists to a fire ant receptor for a pheromone biosynthesis-activating neuropeptide/pyrokinin (pban/pyrokinin) gene derived neuropeptide ligand. Also disclosed are methods of controlling fire ants with the bioactive peptides disclosed herein.
The United States Of America, As Represented By The Secretary Of Agriculture


Processing cartridge, photoreceptor drum unit, and end member pair


A photoreceptor drum unit is provided with a cylindrical photoreceptor drum, and two end members which are respectively disposed at both ends of the photoreceptor drum in an axial direction. One of the end members is provided with an elastic member, is biased in the axial direction, and is extendable and contractable.
Mitsubishi Chemical Corporation


Methods of monitoring immune responses


The human hla-a2:1g dimer molecule is a recombinant protein comprising a mouse igg antibody fused with two human mhc class i hla-a2 molecules. Any peptide (usually 8-10 amino acids in length) can be loaded into the peptide-binding groove of the two hla molecules, for example, by incubating a mixture of the dimer and peptide solution overnight.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


Methods of determining interferon having direct inhibitory effects on tumors and uses thereof


The invention provides novel methods of determining or comparing potency of a test interferon relative to rsifn-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rsifn-co; methods for down-regulation of expression of wnt-related receptors or co-receptors, such as lrp6/fzd6; down-regulation of expression of wnt-related target genes, such as, axin2, cd24, survivin and/or id2; inhibition of beta-catenin/tcf transcriptional activities; suppression of expression of beta-catenin; up-regulation of tumor suppressor genes, such as dkk-3, batf2 and/or klf4; inhibition of tumor cell viability in vitro; inhibition of tumor growth and metastases in vivo; inhibition of tumor cell migration, pseudopod formation, and colony formation in vitro; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.. .
Superlab Far East Limited


Improvements relating to lightning protection systems for wind turbine blades


A blade tip assembly for a wind turbine blade, comprising a conductive blade tip module, a receptor arrangement spaced from the conductive blade tip module, a coupler that electrically couples the conductive blade tip module to the receptor arrangement and an insulating member that insulates the coupler. The invention also can be expressed as a method for assembling a blade tip assembly for a wind turbine blade, the method comprising providing a blade tip module; providing the blade tip module with a coupler for electrically coupling the blade tip module to a down conductor of a lightning protection system; and encasing the coupler with an insulating member..
Vestas Wind Systems A/s


Estrogen receptor alleles that are predictive of increased susceptibility to bone fracture


In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the p, p x, and x alleles of the estrogen receptor α gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject..
Bodysync, Inc.


Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system


This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression.
Intrexon Corporation


Methods and compositions for treatment of angelman syndrome and autism spectrum disorders


Methods for the treatment of angelman syndrome autism spectrum disorders are provided. The methods comprise administrating to a subject an agent that increases the expression of, or increases activity of, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (ampar) at neuronal synapses..
Children's Medical Center Corporation


Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target


The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


Reprogramming t cells and hematopoietic cells


Methods and compositions relating to the production of induced pluripotent stem cells (ips cells) are disclosed. For example, induced pluripotent stem cells may be generated from cd34+ hematopoietic cells, such as human cd34+blood progenitor cells, or t cells.
Cellular Dynamics International, Inc.


Monoclonal antibody which specifically recognizes b cell lymphoma and use thereof


Provided is a monoclonal antibody which specifically recognizes b cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating b cell lymphoma including the monoclonal antibody; a composition for diagnosing b cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing b cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (car) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the car protein; a car-modified t cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating b cell lymphoma including the car-modified t cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated..
National Cancer Center


Method of treating stress hyperglycemia with human antibodies to the glucagon receptor


The present invention provides antibodies that bind to the human glucagon receptor, designated gcgr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gcgr.
Regeneron Pharmaceuticals, Inc.


Glucagon-glp-1-gip triple agonist compounds


The present invention relates to compounds which have agonist activity at the glucagon, gip and glp-1 receptors, and to their use in the treatment of metabolic disorders.. .
Zealand Pharma A/s


Kappa opioid receptor effectors and uses thereof


The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.. .
The Scripps Research Institute


Modulators of resistant androgen receptor


The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (ar), compositions thereof, and methods of making and using the same.. .
Memorial Sloan-kettering Cancer Center


Novel compounds


The present invention is directed to crystalline forms of a compound which has retinoid-related orphan receptor gamma (rorγ) modulator activity, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.. .
Glaxosmithkline Llc


Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer


Wherein r20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; y is s, o, s(═o), —s(═o)(═o)—, or nr10, wherein r10 is h or alkyl; r21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; x is —c(═o)—, —s(═o)(═o)—, or —n(h)c(═o)—; r22 includes at least one divalent amino radical; r23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.. .

Heterocyclic compounds and methods for their use


The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration..
Novartis Ag


Cannabinoid receptor mediating compounds


A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a cb1 receptor mediating scaffold and (ii) a second therapeutic scaffold.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Antidiabetic tricyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.5582

4804

3 - 0 - 106